A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

Phase 1 Completed 31 enrolled Innovent Biologics (Suzhou) Co. Ltd.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.

Timeline

Start: 2019-04-15
Primary completion: 2020-03-05
Completion: 2020-04-10

Publications

Yang S, Li T, Jia H, Gao M, Li Y, Wan X, Huang Z, Li M, Zhai Y, Li X, Yang X, Wang T, Liang J, Gu Q, Luo X, Qian L, Lu S, Liu J, Song Y, Wang F, Sun X, Yu D. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med. 2022 Jun;14(647):eabj2177. doi: 10.1126/scitranslmed.abj2177. Epub 2022 Jun 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	efdamrofusp alfa	Protein / enzyme biologic	0.05 mg	Intravitreal
Subject	efdamrofusp alfa	Protein / enzyme biologic	0.15 mg	Intravitreal
Subject	efdamrofusp alfa	Protein / enzyme biologic	0.5 mg	Intravitreal
Subject	efdamrofusp alfa	Protein / enzyme biologic	1 mg	Intravitreal
Subject	efdamrofusp alfa	Protein / enzyme biologic	2 mg	Intravitreal
Subject	efdamrofusp alfa	Protein / enzyme biologic	4 mg	Intravitreal

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

Summary

Timeline

Publications

Drugs

Indications